Matthew Hamilton reports in Capitol Confidential that New York and 19 other states filed a federal antitrust lawsuit against six generic drug makers alleging the companies entered into numerous illegal conspiracies to favorably affect the market for an antibiotic and an oral diabetes medication. New York Attorney General Eric Schneiderman’s office announced the lawsuit Dec. 15 against Heritage Pharmaceuticals, Aurobindo Pharma USA, Citron Pharma, Mayne Pharma, Mylan Pharmaceuticals, and Teva Pharmaceuticals USA. The companies artificially inflated prices and reduced competition in the United States for doxycycline hyclate delayed release, the antibiotic, and glyburide, the oral diabetes drug, the lawsuit alleges. “Generic drugs play a critical role in moderating healthcare costs for all New Yorkers,” Schneiderman said in a statement. “Companies that collude and fix prices for generic drugs in order to pad their profits must be held accountable for the very real harm they inflict on New Yorkers’ ability to pay for life-saving medications.” Read the full story in Capitol Confidential.